No clinical trial has compared osimertinib as a first-line treatment versus first-generation EGFR-TKI in the first-line treatment until disease progression followed by osimertinib treatment in second-line for patients with EGFR p.Thr790Met mutation-positive NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.